# The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19

> **NCT04588441** · PHASE2 · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Acute Respiratory Distress

## Interventions

- **DRUG:** Adenosine

## Key facts

- **NCT ID:** NCT04588441
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started due to need for additional preclinical work requested by FDA\>
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588441, "The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04588441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*